Table 3 Overview of sensitivity analyses
Withdrawal reasons | Assignment of patients in: | ||||
|---|---|---|---|---|---|
Primary analysis | Sensitivity analysis | ||||
| Â | A | B | C | Da | |
The patient experiences a CIDP relapse during the SC treatment period (lack of efficacy) | Relapser | Relapser | Relapser | Relapser | Relapser |
The investigator advises that the patient’s safety or wellbeing could be compromised by further participation in the study (physician decision) | Relapser | Non-relapsers | Relapser | Not used for analysis | Censored |
The patient receives prohibited medication (protocol violation) | Censored | ||||
Other withdrawal reason (other, adverse event, death, lost to follow-up, protocol violation, study termination by sponsor, and withdrawal by patient) | Non-relapsers | Censored | |||
Patient continues to study end | Non-relapsers | Non-relapsers | Non-relapsers | Non-relapsers | Non-relapsers |